Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.

Aarntzen EH, de Vries IJ, Göertz JH, Beldhuis-Valkis M, Brouwers HM, van de Rakt MW, van der Molen RG, Punt CJ, Adema GJ, Tacken PJ, Joosten I, Jacobs JF.

Cancer Immunol Immunother. 2012 Nov;61(11):2003-11. doi: 10.1007/s00262-012-1263-z. Epub 2012 Apr 21.

2.

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.

Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ.

Clin Cancer Res. 2003 Nov 1;9(14):5214-20.

3.

Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.

Rieser C, Ramoner R, Höltl L, Rogatsch H, Papesh C, Stenzl A, Bartsch G, Thurnher M.

Urol Int. 1999;63(3):151-9.

PMID:
10738185
4.

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.

PMID:
15726361
5.
6.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG.

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.

7.

Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.

Livingston P, Zhang S, Adluri S, Yao TJ, Graeber L, Ragupathi G, Helling F, Fleisher M.

Cancer Immunol Immunother. 1997 Jan;43(6):324-30.

PMID:
9067403
9.

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.

Blood. 1999 Apr 1;93(7):2411-9.

10.

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE 2nd, Friedman HS, Bigner DD, Sampson JH.

J Immunol Methods. 2008 Nov 30;339(1):74-81. doi: 10.1016/j.jim.2008.08.004. Epub 2008 Sep 4.

PMID:
18775433
12.

Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.

Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ.

Clin Cancer Res. 2010 Oct 15;16(20):5067-78. doi: 10.1158/1078-0432.CCR-10-1757. Epub 2010 Aug 24.

13.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ.

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11.

PMID:
21069321
14.
15.

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ.

Clin Cancer Res. 2003 Nov 1;9(14):5091-100.

16.

Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats.

Kawai R, Ito S, Aida T, Hattori H, Kimura T, Furukawa T, Mori K, Sanbuissho A, Kawada T.

J Immunotoxicol. 2013 Jan-Mar;10(1):40-8. doi: 10.3109/1547691X.2012.691122. Epub 2012 Sep 7.

PMID:
22953734
17.

Evaluation of canine T-cell dependent antibody response to the primary and secondary immunization with keyhole limpet hemocyanin.

Kawai R, Aida T, Hattori H, Furukawa T, Mori K, Takasaki W, Takahashi N, Kawada T.

J Toxicol Sci. 2013;38(4):571-9.

18.

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO.

Int J Cancer. 2000 Mar 1;85(5):659-66.

19.

Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J.

Cancer Res. 2001 Sep 1;61(17):6451-8.

20.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.

PMID:
12439347

Supplemental Content

Support Center